LSTALisata Therapeutics, Inc.Finished
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Cholangiocarcinoma · Gallbladder Cancer · Gallbladder Carcinoma · Intrahepatic Cholangiocarcinoma · Extrahepatic Cholangiocarcinoma · Bile Duct Cancer · Gall Bladder Cancer · Gall Bladder Carcinoma
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +5.1
A key executive is leaving
Since Aug 4, 2026 · was worth 15, fading over time
- +5.1
Announced layoffs or restructuring
Since Aug 4, 2026 · was worth 15, fading over time
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 66 (final count)
- Started
- May 13, 2023
- Main results expected
- Apr 5, 2026
- Fully finished
- Apr 5, 2026
- Results posted
- May 26, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Subjects Experiencing Any Adverse Event
Measured over: From time of consent until 30 days after treatment discontinuation, up to 18 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 5.1, since 2026-08-04, fades (half-life) · source filing
- layoffs: base 15, now 5.1, since 2026-08-04, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT05712356 · record last updated 2026-09-28 · checked 2026-11-09 15:47 UTC